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Myotonic dystrophies are multisystemic diseases characterized not only by muscle and
heart dysfunction but also by CNS alteration. They are now recognized as brain diseases
affecting newborns and children for myotonic dystrophy type 1 and adults for both
myotonic dystrophy type 1 and type 2. In the past two decades, much progress has
been made in understanding the mechanisms underlying the DM symptoms allowing
development of new molecular therapeutic tools with the ultimate aim of curing the
disease. This review describes the state of the art for the characterization of CNS related
symptoms, the development of molecular strategies to target the CNS as well as the
available tools for screening and testing new possible treatments.
Keywords: myotonic dystrophy, trinucleotide repeat diseases, DM CNS symptoms, therapeutic strategies, animal
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GENERAL FEATURES AND MECHANISMS
Myotonic dystrophies (DM1 and DM2) are autosomal dominant multisystemic diseases (Harper,
2001). Both are associated not only with myotonia and progressive muscle weakness, but also
with broad clinical features including heart conductions defects and central nervous system (CNS)
alterations. DM type 1 and type 2 are highly variable in term of age at onset, severity of the
symptoms, clinical pictures, both in and between the two types. Anticipation, with aggravation of
the disease severity and earlier age at onset through successive generations, is particularly evident
in DM1 that can affect adults and children at birth (congenital DM1, CDM) or during childhood.
Identification in 1992 of the mutation underlying DM1 in the DMPK gene on chromosome 19
revealed, at least in part, clues to understand this particular mode of transmission of the disease.
The very highly unstable CTG repeat expansion involved in DM1 usually increases from one
generation to the next and is more or less associated with the disease severity (Harper, 2001).
Patients with DM1 can be divided into five main categories, each presenting specific clinical
features and management problems: congenital, childhood-onset, juvenile, adult-onset, and late-
onset/asymptomatic. The five clinical forms distinguish from each other by the prevalence of
the main symptoms as their apparition profiles. This new classification appears to be useful in
the Context of emerging therapeutic approaches and in harmonization of international myotonic
dystrophy network (IDMC—International Myotonic Dystrophy Consortium; De Antonio et al.,
2016). Table 1 summarizes these subtypes:
Congenital DM1 (CDM) shows a distinct clinical phenotype with distinct clinical features
therefore it is not to be considered a severe early form of “classical” DM1. CDM often presents
before birth as polyhydramnios and reduced fetal movements. After delivery, the main features are
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TABLE 1 | Summary of DM1 main clinical phenotypes and CNS related symptoms.
Phenotypes Age of onset Clinical findings* CNS symptoms* CTG length
Congenital Birth Infantile hypotonia
Respiratory failure
Feeding difficulties
Cardiorespiratory complications
Learning disability
Reduced IQ values
Speech and language delay
>1,000
Childhood onset 1–10 years Facial weakness
Myotonia
Heart Conduction defects
Reduced IQ values
Attention deficit
Deficit in visuo-spatial/constructive skills
Autism spectrum disorder
Communication problems
Social anxiety
Fatigue
50–1000
Juvenile 10–20 years Classical motor and heart symptoms can be
absent and can appear later on
Visuo-spatial deficit Executive dysfunction
Learning difficulty Social and Mating problems
50–1000
Adult onset 20–40 years Weakness
Myotonia
Cataracts
Conduction
defects
Insulin resistance
Respiratory failure
Lower IQ scores
Frontal dysexecutive syndrome
Apathy
Avoidant personality
Lack of initiative
Social interactions problems
Theory of mind deficit Fatigue Sleepiness
50–1000
Late onset/Asymptomatic >40 years Mild myotonia Cataracts 50–100
Pre-mutation N/A None 38–49
*Note that the described features can be very variable from one individual to another
N/A, Not applicable.
severe generalized weakness, hypotonia, and respiratory
compromise. Mortality from respiratory failure is high.
Surviving infants experience gradual improvement in motor
function, almost all CDM children are able to walk. Cognitive and
motor milestones are delayed and all patients with CDM develop
learning difficulties and require special schooling needs. A
progressive myopathy and the other features seen in the classical
form of DM1 can develop although this does not start until
early adulthood and usually progresses slowly (Harper, 2001).
Clinical myotonia is neither a feature presented in the neonatal
period nor can it be disclosed in the electromyogram (EMG).
Patients often develop severe problems from cardiorespiratory
complications in their third and fourth decades.
The diagnosis of the DM1 childhood onset form is
often missed in affected adolescents or children because of
uncharacteristic symptoms for a muscular dystrophy and
apparently negative family history (Harper, 2001). These patients
have cognitive deficits and learning abnormalities (Steyaert et al.,
1997) and, as in the congenital cases, degenerative features often
develop as these children reach adulthood. There is increasing
evidence of early heart conduction abnormalities thus annual
electrocardiograms and consideration of electrophysiological
studies should be a part of routine management.
The juvenile form with age at onset at 11 years is characterized
by school and mating problems and is often under-recognized.
These childhood and infantile forms should be considered rather
as a CNS disease than a muscular or systemic disease (see
Neuropsychiatric Section).
The core features in adult-onset DM1 are distal muscle
weakness, leading to difficulty with performing tasks requiring
fine dexterity of the hands and foot drop, and facial weakness
and wasting, giving rise to ptosis and the typical myopathic or
“hatchet” appearance. The neck flexors and finger/wrist flexors
are also commonly involved. Grip and percussion myotonia
are regular features; however, myotonia affects other muscle
including bulbar, tongue, or facial muscles, causing problems
with talking, chewing, and swallowing. Elevation of the serum
creatine kinase is sometimes present. Cardiac involvement is
common in DM1 and includes conduction abnormalities with
arrhythmia and conduction blocks contributing significantly
to the morbidity and mortality of the disease (Bassez et al.,
2004; Chebel et al., 2005; Montella et al., 2005; Russo et al.,
2006). In some patients and families, a dilated cardiomyopathy
may be observed. Posterior subcapsular cataracts develop in
most patients and some patients may develop cataract at
an early age without any other symptoms (Garrott et al.,
2004). Nocturnal apnoeic episodes and daytime sleepiness are
a common manifestations (Laberge et al., 2004). Periodic
limb movements in DM1 are also frequently associated
(Romigi et al., 2011). Gastrointestinal tract involvement covers
irritable bowel syndrome, symptomatic gall stones and gamma-
glutamyltransferase elevations. Finally, endocrine abnormalities
include testicular atrophy, hypotestosteronism, insulin resistance
with usually mild type-2 diabetes. Severe Vit. D deficiency
is common in DM1 and it is associated with secondary
hyperparathyroidism and primary hyperparathyroidism, though
rare may occur. Therefore greater attention should be given to
Vit. D status, in order to administer an appropriate replacement
theraphy (Passeri et al., 2015).
In late-onset or asymptomatic DM1 patients myotonia,
weakness, and excessive daytime sleepiness are rarely present.
Before DNA tests became available, there were many examples
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 April 2017 | Volume 11 | Article 101
Gourdon and Meola Therapeutic Developments for DM CNS
of incorrect ascertainment, even when using markers such as
EMG evidence of myotonia and slit-lamp examination for the
characteristic cataracts (Barnes and Hilton-jones, 1994). In late-
onset patients, the search for cataracts is helpful for identifying
the transmitting person.
About 20 years ago, while studies following the discovery
of the DM1 peculiar mutation concentrated mainly on CTG
metabolism and direct consequences on neighboring genes,
identification of the CCTG expansion in DM2 (in the CNBP gene
on chromosome 3) helped to provide important milestones to
understand how a single mutation can affect so many tissues
with such high variability (Liquori et al., 2001). Briefly, the
consequences in cascade of CTG and CCTG expansions can be
illustrated as a branching tree showing the complex mechanisms
involved and the deregulation of many intermediates and final
targeted genes (Figure 1). It is clear now that RNAs carrying
CUG or CCUG expansions are forming ribonuclear foci easily
visible with fluorescent oligonucleotide probes. These foci are
trapped into the nucleus of cells expressing the gene involved,
during development and in various tissues. They affect a subset
of proteins that can be called “mediators” such as MBNL and
CELF proteins and others proteins (Pettersson et al., 2015).
These mediators are directly affected by RNA foci themselves
through direct sequestration (e.g., MBNL) or by triggering
stabilization (e.g., CELF stabilized by PKC and/or GSK3ß). In
turn, deregulation of the available steady state of mediators
disturb various molecular cell processes including transcription,
splicing, polyadenylation,mRNA stability, and transport, miRNA
and RNAi regulation, conventional and RAN translations (Sicot
et al., 2011; Jones et al., 2012; Batra et al., 2014; Kino et al.,
2015). In subsequent steps, many other “downstream target
genes” will be affected at different molecular levels, which
will lead to various cellular processes deregulation in tissues
expressing both toxic RNAs and at least part of the mediators.
One can predict that severity of mutation toxicity will depend
on mutant transcripts levels, on concomitant expression of
different mediators through development and in various tissues
and finally, on mediators dose-dependency of downstream
target RNAs (Jog et al., 2012; Wagner et al., 2016). Regarding
CNS, toxic RNA foci are observed in many brain regions,
in different cell types and splicing defects have also been
reported (Figure 1; Jiang et al., 2004; Caillet-Boudin et al.,
2014). This suggests that RNA toxicity and downstream steps
involving mediators that can be common with other tissues or
specific to brain are also underlying CNS dysfunction in DM
patients. Interestingly, MBNL2 appears to be a key actor in
DM CNS (Charizanis et al., 2012; Goodwin et al., 2015) but
CELF proteins are also very probably involved (Hernández-
Hernández et al., 2013; Ladd, 2013; Caillet-Boudin et al., 2014).
Nevertheless, little is known about links between the molecular
defects and the various symptoms related to CNS. Considered
at first sight as muscle and heart disease, growing clinical,
neuropsychological, imaging, and histopathological evidence as
well as family testimonies demonstrated that DM1 but also DM2,
however to a lesser extent, are true brain disorders (Meola,
2010).
FIGURE 1 | Complexity of myotonic dystrophies. The different cellular processes affected by the CTG and CCTG mutations and toxic RNAs are indicated in gray.
The possible “mediator” proteins are written in the branches and some of downstream affected genes known so far are named red. The 4 possible entries for
therapies are shown on the right side.
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NEUROPSYCHIATRIC, COGNITIVE, AND
OTHER NEUROLOGICAL SYMPTOMS
(ADULTS, INFANTS AND CDM)
Involvement of the CNS in DM has been first documented in
patients with early DM1 onset (congenital or during childhood).
CDM (usually >1,000 repeats) is the most severe form of DM1
and may present prenatally with polyhydramnios and decreased
fetal movements. At birth, respiratory failure, hypotonia, and
feeding difficulties are common. Infants have facial weakness
and a characteristic “tented” or “fish-shaped” upper lip (Harper,
2001; Echenne and Bassez, 2013). The mortality rate at birth
is high. For the children that pass the critical neonatal
period, the developmental profile (especially motor and language
skills) improved in early childhood and apparently faster
in boys (Prasad et al., 2016). However, moderate to severe
intellectual disabilities, reduced IQ-values, speech and language
delay, deficit in visuospatial and/or visuo-constructive skills,
attention deficit with or without hyperactivity disorder (ADHD),
autism spectrum disorder, problems with communication and
social anxiety have been reported by several authors in DM1
childhood patients (Angeard et al., 2007, 2011; Meola and
Sansone, 2007; Ekström et al., 2008, 2009; Douniol et al., 2009,
2012). Interestingly, a survey distributed to parents of affected
child revealed that problems with communication and fatigue
appeared to have the greatest impact on childrens’ lives (Johnson
et al., 2014). It is important to note that in the juvenile form,
classical neurological or motor symptoms can be absent and
that cognitive (visuo-spatial deficit and executive dysfunction,
learning difficulty) or psychiatric symptoms (social mating with
peers) can be the only clinical manifestations of the disease.
Executive dysfunction reduces initiative, planning abilities and
decision making and leads to apathy and inactivity which may
have significant influence on quality of life in this cohort of
patients.
In adult DM1 patients, cognitive impairment with lower
IQ scores is a variable but common feature, even in the least
severe form (Jean et al., 2014). Several studies highlight higher–
order impairments in executive functions, verbal and non-
verbal episodic memory, spatial and visuo-constructive abilities
suggestive of a frontal dysexecutive syndrome (Rubinsztein
et al., 1998; Modoni et al., 2004; Meola and Sansone, 2007;
Sansone et al., 2007). DM1 patients are described as apathetic,
with avoidant personality and lack of initiative and they
have severe difficulties in daily-living activities including social
interactions. Apathy seems to be associated with cognitive
status and frontal lobe dysfunction independently of fatigue,
sleepiness, age, gender, motor disability, and psychopathological
domain (Gallais et al., 2015). This may play role in delay of
treatment or diagnosis and studies are ongoing to understand the
influencing neuropsychological factors. A large number of DM
1 patients showed reduced ability to recognize facial expressions
in recognition tasks and have difficulty in understanding others’
mental states from both interaction with others in everyday
situations and from their facial expressions. They are impaired
in tests assessing the theory of mind (ToM, ability to infer
other people’s mental states, thoughts and feelings; Takeda et al.,
2009; Kobayakawa et al., 2010, 2012; Masaoka et al., 2011;
Winblad et al., 2016). In addition, reduced awareness of disease
burden is common (Baldanzi et al., 2016a). Beside cognitive and
behavioral features, DM1 patients suffer from excessive daytime
sleepiness (EDS), sleep apneas, periodic leg movements during
sleep. Furthermore, rapid eye movement sleep deregulation and
longer habitual nocturnal sleep are reported (Laberge et al.,
2009; Heatwole et al., 2012). It has been proposed that EDS is
primarily caused by a central dysfunction of sleep regulation
while both respiratory muscles (weakness and myotonia) and
abnormalities of central control of ventilation contribute to
sleep-related disordered breathing (SRDB; Laberge et al., 2013).
Fatigue is a major complaint reported by the DM1 patients
(Angelini and Tasca, 2012; Heatwole et al., 2012). The origin
of this fatigue is complex and can involve both central and
peripheral component, fatigue as a sense of tiredness might
primarily result from CNS dysfunction (Angelini and Tasca,
2012). These symptoms increase the impact of the disease on
social life, and quality of life (Laberge et al., 2009; Heatwole
et al., 2012). In a Japanese small cohort of 7 DM1 patients,
although DM1 patients had normal olfactory detection (except
for 1 out of 7), they exhibited decreased or impaired odor
recognition abilities. The loss of odor recognition abilities could
be associated with changes in the limbic areas and could represent
an interesting biomarker of neurological disease such as DM
(Masaoka et al., 2011, 2013). In addition to neuropsychiatric
and cognitive symptoms, large epidemiologic studies revealed an
increased oncologic risk in DM1 brain, with astrocytoma as the
most common subtype (Fernández-Torrón et al., 2016; Gadalla
et al., 2016).
Patients with DM2 have also a frontal dysexecutive
syndrome with apathy, reduced initiative, and strategic abilities.
Visuospatial and executive dysfunctions seemed to be the main
cognitive defects, while memory and language impairments
appeared in more severe phenotypes. Avoidant personality have
been reported but milder in DM2 patients compared to DM1
patients (Meola and Cardani, 2015; Peric et al., 2016). Similar
to DM1, fatigue, and impaired sleep or daytime sleepiness are
reported among the themes with the highest life impact score
(Heatwole et al., 2015). The milder CNS phenotype in DM2
in comparison to DM1 is not well known and may be caused
by complex unraveled pathomolecular mechanisms including
possible unidentified modifier genes (Meola and Cardani, 2017).
IMAGING FEATURES
The last 20 years showed a significant increase of different
imaging studies both in DM1 and DM2, which confirms the
recognition of DM1 as a brain disease. DM1 congenital cases
show ventricular enlargement, cortical atrophy and small corpus
callosum (Hashimoto et al., 1995; Harper, 2001; Mutchnick et al.,
2016). Diffuse T2-hyperintense white matter signals were also
reported (Harper, 2001; Bosemani et al., 2014). In young affected
children and adolescent, Diffusion Tensor Imaging (DTI) showed
significant microstructural white matter abnormalities in frontal,
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temporal, parietal, and occipital lobar regions. Interestingly,
the overall degree of white matter disturbance, was correlated
with the working memory deficits (Wozniak et al., 2011, 2014).
The observation that in juvenile DM1 patient white matter
abnormalities exceeded gray matter strengthen the hypothesis
according which developmental changes would be responsible
for microstructural white matter alterations in congenital or
children cases while gray matter changes would originate from
degenerative processes in adult DM1 patients (Caso et al., 2014).
In adult DM1 patient, there is also evidence for CNS atrophy
significantly correlated with age, possibly indicating progression
with time (Baldanzi et al., 2016b). Atrophy appears widely
distributed and can be associated with executive dysfunction
and with memory and visuo-spatial impairments (Meola et al.,
1999; Schneider-Gold et al., 2015; Baldanzi et al., 2016b).
Abnormalities in white matter tracts were reported throughout
the brain (Harper, 2001; Minnerop et al., 2011; Wozniak et al.,
2014; Baldanzi et al., 2016b) as well as dilated Virchow–
Robin spaces (DVRS; Renard et al., 2016), reduced cerebral
glucose metabolism and cerebral blood flow (Mielke et al.,
1993; Annane et al., 1998; Meola et al., 1999, 2003; Romeo
et al., 2010) and hypoperfusion (Meola et al., 2003; Romeo
et al., 2010). Abnormalities in cerebral metabolites were found
in DM1 patients suggesting global neuronal impairment or
FIGURE 2 | Local atrophy of gray matter (GM) and white matter (WM) in DM patients. (A) Local atrophy of GM (yellow) and WM (blue) in 12 DM1 patients
compared to 28 healthy controls. (B) Local atrophy of GM (yellow) and WM (blue) in 15 DM2 patients compared to 28 healthy controls. Voxelwise multiple regression
analysis with group and age as covariates. Age was used as a covariate of no interest. Areas with adjusted p at cluster level <0.05 after FWE correction are shown; X,
Y, Z: MNI-coordinates: negative X-values reflect left side and positive X-values right sided location. Adapted from Schneider-Gold et al. (2015).
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neuronal loss as well as abnormalities in the glutamatergic
system within the frontal lobe of patients with DM1 (Vielhaber
et al., 2006; Takado et al., 2015). DM2 patients share some of
these features but to a lesser extent (Minnerop et al., 2011;
Meola and Cardani, 2015). In addition, structural imaging
studies have shown widespread gray matter changes both in
DM1 and DM2 patients (Antonini, 2004; Ota et al., 2006;
Minnerop et al., 2008; Weber et al., 2010; Schneider-Gold
et al., 2015; Serra et al., 2015; Baldanzi et al., 2016b; Zanigni
et al., 2016). Gray and white matter local atrophies detected in
DM patients using 3T MRI, Voxel-based morphometry (VBM),
and Statistical Parametric Mapping (SPM) are illustrated in
Figure 2.
CORRELATION IMAGING
FEATURES/NEUROLOGICAL SYMPTOMS
Imaging could be a very useful and non-invasive technique
for monitoring DM patients during clinical trials. However,
strong correlations between observed imaging characteristics
and other CNS symptoms must be clearly demonstrated. White
matter abnormalities including microstructural damage have
been correlated in DM1 patients with cognitive deficits including
working memory, processing speed, executive, reasoning, and
visuo-spatial impairment, orientation, and attention deficits
(Weber et al., 2010; Wozniak et al., 2013, 2014; Caso et al.,
2014; Bajrami et al., 2017; Baldanzi et al., 2016b). Sleepiness
in DM1 was found inversely associated with white matter fiber
integrity (Wozniak et al., 2013). Correlations were found between
the sensitivity to facial emotions and frontal, temporal, and
insular white matter lesions (Takeda et al., 2009; Kobayakawa
et al., 2010). Interestingly, comparison of DM1 and DM2 patients
cohorts revealed widespread cortical and subcortical gray matter
and white matter atrophy in both types of DM patients especially
in the central motor pathways in DM1 and limbic structures in
DM2 in correlation with motor dysfunction, cognitive abilities
depression, daytime sleepiness, and reduced executive functions
(Schneider-Gold et al., 2015; Serra et al., 2015). Furthermore,
voxel-based morphometry (VBM) showed bilateral hippocampal
decrease in gray matter that correlated to episodic memory
deficits in both patient groups (Weber et al., 2010). Transcranial
sonography (TCS) studies found pathological brainstem raphe
signals associated with excessive daytime sleepiness in DM1 and
DM2 patients as well as with fatigue in DM2 patients (Krogias
et al., 2014; Peric et al., 2014b; Rakocevic-stojanovic et al.,
2016). Functional near-infrared spectroscopy (fNIRS) performed
in DM1 patients revealed a correlation between left prefrontal
cortex hypometabolism with frontal cognitive performances in
DM1 (Caliandro et al., 2013). Changes on brain functional
connectivity correlates with atypical personality profiles and
Theory of mind (ToM) deficit (Serra et al., 2016a,b). The
ToM dysfunctions support the hypothesis that differences in
social interactions and personal relationships are consequence of
brain connectomics abnormalities and not a reaction symptom.
Very interesting is the combining study of cerebral and muscle
MRI abnormalities in 10 DM1 (5 congenital and 5 adult)
vs. DM2 and controls. A significant difference in the white
matter integrity was found in DM compared to controls. In
parallel, masticatory muscle volumes were significantly reduced
in congenital and adult DM1 compared to controls. All these
findings suggest a common mechanism underlying the severity
of both muscle and cerebral pathology in DM1 (Franc et al.,
2012).
Altogether, the imaging analyses and the attempt to correlate
pathological brain changes with cognitive dysfunction or
personality profiles suggest that complex neuronal networks
involving numerous CNS regions and mechanisms related
to plasticity, neurodevelopmental, and neurodegeneration are
implicated in myotonic dystrophies.
PROGRESSION OF CNS SYMPTOMS WITH
AGE
In order to design future therapeutic trials to target the
CNS, it is essential to determine how symptoms change
over time. Very recently, two studies have reported for DM1
patients, a cognitive decline on longitudinal studies of 5 or
9 years especially for verbal memory, attention, visuo-spatial
construction, and processing speed (Gallais et al., 2017; Winblad
et al., 2016). In particular, the Swedish study showed that
cognitive decline in adult DM1 correlated with earlier onset
and longer duration of the disease suggesting a degenerative
process, while the Canadian study supported the hypothesis of
a progeroid disease (accelerated and increased aging process).
However, these recent studies reinforce the previous observation
of Sansone et al who observed a progression of frontal
cognitive impairment (attention) both in DM1 and DM2 patients
(Sansone et al., 2007). Regarding imaging, recent retrospective
MRI evaluation of DM1 patients over 13.4 (± 3.8) years
demonstrated that white matter lesions progressed over time
although with variable extent depending on the tested patients
and families. This suggests a degenerative process of white matter
abnormalities in adults DM1 patients (Conforti et al., 2016).
Half of the 13 patients of this longitudinal studies showed
abnormal ventricular enlargement with time. Unfortunately,
brain volumetric techniques were not available at the time
of the first MRI observations in this retrospective study.
Therefore, more longitudinal studies are needed to accurately
determine the level of progression both on white matter and
gray matter abnormalities and on more homogeneous cohort
of patients (congenital, childhood, juvenile, adult, late-onset).
Overall, the interplay between neurological, psychological and
social factors can be complex warranting referral to behavioral
medicine specialists for neuropsychological testing, evaluation,
and treatment. Physicians should remain vigilant of possible
substance abuse, child neglect, financial needs, socioeconomic
circumstances, personal hygiene, home safety, and unsafe
driving. Referral to appropriate social service, local support
groups, and organization may be advantageous. There is the
current effort to develop care guidelines for patients with
myotonic dystrophy that would address the CNS abnormalities
as well quality of life.
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HISTOPATHOLOGY
A variety of histopathological features have been observed in
postmortemDMbrain samples. These CNS pathological changes
include pre-senile neurofibrillary tangles observed both in DM1
and DM2 brains, Marinesco bodies observed mainly in DM2 and
granulovacuolar degeneration (reviewed in Caillet-Boudin et al.,
2014). Abnormal tau pathology by immunohistochemistry on
brain tissues was found both in DM1 and DM2 (Maurage et al.,
2007). Loss of serotonin-containing neurons was observed in
relation to hypersomnia (Ono et al., 1998). Heterotopic neurons
have been reported in the brain and spinal cord of autopsiedDM1
patient with CDM or childhood onset with intellectual deficiency
suggesting neurodevelopmental abnormalities (Watanabe et al.,
1997). The molecular hallmarks of DM, RNA nuclear foci, are
detected in post-mortem DM1 brain tissues as soon as 12–13.5
week (Michel et al., 2015). In DM1 adult post-mortem samples,
RNA foci are widely distributed throughout cortical layers, in
various brain region, in neurons, astrocytes, oligodendocytes,
Purkinje cells as well as in human DM1 iPS or ES-cell-derived
neural stem cells (NSCs; Jiang et al., 2004; Denis et al., 2013;
Hernández-Hernández et al., 2013). In nuclei, they do not co-
localize with PML bodies, nucleolus, perinuclear compartment,
or speckles. However, in cortical neurons three components of
the proteasome appear recruited by the RNA foci. Moreover, as in
muscle cells, RNA foci observed in brain co-localize withMBNL1
and MBNL2 (Jiang et al., 2004).
DM BIOMARKERS FOR CNS
ABNORMALITIES
CNS biomarkers that could be useful for clinical trials were
investigated both in blood and cerebrospinal fluid (CSF).
Biomarkers of neurodegeneration such as tau and amyloid ß42
protein (Aß42) were investigated in juvenile and adult DM1
patients. A significant decrease of CSF levels of Aß42 was
reported as well as increase of the levels of total tau protein
(Winblad et al., 2008; Peric et al., 2014a). No correlation between
the levels of these CSF biomarkers and neuropsychological
impairment were evident. However, they could reflect an
alteration of the permeability of the brain blood barrier (BBB)
and then represent suitable markers for DM1 patients (Bosco
et al., 2015). In addition, increase in CSF IgG, γ-globulin, and
possibly in myelin basic protein (MBP) similar to that observed
in demyelinating diseases have been reported in DM1 patients
(Hirase and Araki, 1984). Interestingly, a decrease of the brain
derived-neurotrophic factor (BDNF) was reported recently in the
serum of DM1 patients. BDNF is a neurotrophin involved in
learning and memory. As it can cross the brain blood barrier, it
could be considered as a marker for CNS lesions (Comim et al.,
2015).
CELL AND ANIMAL MODELS
The development of pathological models is an important step not
only to understand mechanisms that link disease mutation and
resulting pathophysiology, but also to screen, identify, and test
new pharmacological molecules or molecular tools (Plantié et al.,
2015). For DM and especially for CNS, a variety of models from
cells to mammalian organisms has recently emerged.
Neural stem cells (NSC) derived from Embryonic Stem cells
(ES) or from induced Pluripotent Stem Cells (iPSCs) developed
in the context of DM1, have shown to recapitulate important
features of DM1 (RNA foci, MBNL sequestration, splicing defect;
Marteyn et al., 2011; Denis et al., 2013; Xia et al., 2013; Xia
and Ashizawa, 2015). DM1 NSC allowed the identification of
new cellular pathways and mechanisms affected by the mutation
such as decreased expression of members of SLITRK family in
relation with neuritogenesis and synaptogenesis (Marteyn et al.,
2011) and defect in mTOR pathway (Denis et al., 2013). C.
elegans was one of the first model organisms to be used in
laboratory especially to study development, and this is one of the
simplest organismwith a nervous system. Interestingly, mutation
in C. elegans Mbl1 gene, that shares orthologous sequence
with drosophila muscleblind and mammalian muscleblind-like
genes induces defect in synapse formation of motor neurons
(probably on the presynaptic side) that translates into abnormal
locomotion of mutated worms (Spilker et al., 2012). Zebrafish
is a simple model organism that has proven to be useful to
study neurogenesis and behavior and for large scale forward and
reverse genetic screens. Knock-down ofMbnl2 induced systemic
abnormalities including brain malformations (Machuca-Tzili
et al., 2011). Expression of (CUG)91 repeat-containing mRNA
in embryo resulted in toxicity in the nervous symptoms
characterized by delayed development of the head and forebrain
structures (Todd et al., 2014). Drosophila melanogaster is also
a widely used model. CNS development is well-known and
multiple useful behavioral tests have been developed. They allow
large scale forward and reverse genetic screens (García-Alcover
et al., 2014). Different size of CTG repeats have been expressed
in flies and CUG repeats over 230 units induce lethality when
expressed in the nervous system (Garcia-Lopez et al., 2008; Yu
et al., 2011).
Although high throughput screening is not really feasible
in mouse models, mice are useful tools to investigate complex
cellular and physiological functions in different tissues and
during development of a mammalian organism. Disease mouse
models are also widely used for preclinical assays, although
more than 80% of potential therapeutics tested in mice fail
when tested in people (Perrin, 2014). Therefore, animal models
for translational research must be characterized in detail and
preclinical testing must be proceed with caution. Concerning
DM and CNS, few models have been developed so far. They
range in two categories that are Mbnl knockout mice and
transgenic mice expressing CTG repeats in the CNS. Mbnl
knockout mice have clearly demonstrated the high impact of
MBNL proteins (MBNL1 and MBNL2) depletion not only in
muscle and heart but also in CNS. Interestingly, comparison
of Mbnl1 knockout with Mbnl2 knockout and with compound
loss of both proteins revealed the major role of MBNL2 in CNS
and new developmental functions for these proteins (Kanadia
et al., 2003; Charizanis et al., 2012; Batra et al., 2014; Goodwin
et al., 2015). Mbnl2 knockout mice show altered REM (rapid
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eye movement) sleep regulation, learning and memory deficit
associated with decreased synaptic GRIN1 activity and impaired
long-term potentiation as well as increase seizure susceptibility
(Charizanis et al., 2012). In addition, transcriptomic analyses
revealed widespread alternative splicing changes in brain. Despite
the preponderant role ofMBNL2 inDMCNS symptoms,MBNL1
could also take part in the story. Indeed, Mbnl1 knockout show
mild misplicing events (Suenaga et al., 2012) as well as behavioral
changes related to lack of motivation (Matynia et al., 2010), a trait
typically observed in DM patients. Furthermore, both MBNL1
and MBNL2 are required for alternative splicing of MAPT exon
2 that is found deregulated in DM patients (Carpentier et al.,
2014). The second type of DM mouse model available to study
CNS features so far, are transgenic mice such as DMSXL mice
(Gomes-Pereira et al., 2007; Hernández-Hernández et al., 2013).
These mice express a human DMPK transgene carrying >1,000
CTG under the control of its own promoter that allows tissue-
specific expression close to that observed in human tissues
(Huguet et al., 2012). They display numerous RNA foci in
various brain regions associated with brain region-specific mild
splicing defects, increase of CELF proteins in frontal cortex
and brainstem, increase seizure susceptibility, deficit in short-
term synaptic plasticity, anxiety, spatial and working memory
impairment, and anhedonia (Charizanis et al., 2012; Hernández-
Hernández et al., 2013). In addition, changes in neurochemical
levels were observed in frontal cortex and brainstem as well
as abnormal expression of synaptic proteins (one of which is
also deregulated in Mbnl knockout mice) indicative of synaptic
dysfunction (Hernández-Hernández et al., 2013). However,
better characterization and standardized protocols are needed to
determine how these different mouse models can be used for
preclinical assays.
POTENTIAL THERAPEUTIC STRATEGIES
TARGETING CNS
More than 16 years ago, even though the DM1 genetic
defect was identified, it remained difficult to propose new
therapeutic strategies for DM, as the mechanisms underlying
these multisystemic diseases were totally unknown. Since the
early 2000s, tremendous progress has been made through
identification of the DM2 mutation (Liquori et al., 2001) and
development of DM animal models (reviewed in Gomes-Pereira
et al., 2011). Since then, new therapeutic tools emerged with
aims to target different steps of the DM pathological cascade
including (1) the DNA mutation itself, (2) toxic RNAs, (3)
mediator proteins, or (4) one of the final targets (Figure 1).
Targeting the more upstream as possible should block the
beginning of the toxic cascade and correct more defects in tissues.
In the context of the multi-systemic DM, the ideal treatment
should be systemic and efficient at least in muscle, heart and
brain. However, one can imagine also combination of different
tissue-specific treatments. The past few years, most efforts have
focused on mutant DMPK RNA in order to eliminate the toxic
RNAs or to release the sequestrated mediators such as MBNL
proteins in muscles (reviewed in Klein et al., 2015). Antisense
oligonucleotides (ASOs, with various chemistry and/or linked
with peptides or nanoparticles) targeting the expanded repeat
or specific DMPK sequences, small molecules, conjugated cell
penetrating peptides (CPPs), miRNA “sponges” and viral-based
gene therapeutic approaches have proven to be efficient in cell
models and to some extent in animal models especially for
muscles (Gao and Cooper, 2013; Klein et al., 2015; Bai et al., 2016;
Cerro-Herreros et al., 2016). Twenty-five years after discovery of
the DM1 mutation and with these validated proofs of concept,
the first phase 1/2a clinical trial was launched in December 2014
using gapmer-ASOs aiming at destroying DMPK transcripts in
muscles (trial NCT02312011). Beside strategies targeting toxic
DMPK RNA to release MBNL proteins, CELF proteins are also
targets to consider. The inhibition of PKC or GSK3β, proteins
known to regulate the phosphorylation of CELF proteins, allowed
the reversal of muscle and heart phenotypes in DM1 mouse
models (Wang et al., 2009; Jones et al., 2012). CELF proteins
(and particularly CELF2) are known to be significant players
in the CNS and thus represent important proteins to target, in
particular with pharmacological means (Ladd, 2013). A phase 2
trial was recently launched to evaluate the safety and efficacy of
tideglusib, a GSK3ß inhibitor (trial NCT02858908). The recent
development of genome editing using TALENs or CRISPR-
Cas nucleases provides for DM a very appealing new field of
investigation (Richard, 2015; Lee et al., 2016; Long et al., 2016).
One can dream to be able to remove the deleterious expansion
directly on DNA correcting definitively the mutation. Recent
studies in yeast, and cell systems have demonstrated the feasibility
to remove or reduce CTG repeats with TALEN or CRISPR-Cas
nucleases (Richard et al., 2014; Cinesi et al., 2016; van Agtmaal
et al., 2017). Furthermore, dual CRISPR-Cas9 cleavages on both
side of the CTG expansions in DM1 myoblasts were able to
eliminate RNA foci and to restore splicing defects and myogenic
capacity (van Agtmaal et al., 2017). However, there is still a long
road before to be able to apply nucleases in Human patients and
to overcome the difficulties (1) to reach all the tissues affected in
DM, (2) to correct DNA in the maximum of cells for restoration
of tissue function, and (3) to secure treatments for minimal
side-effects.
The current therapeutic developments at RNA or DNA
levels should be applicable in principle to the CNS. Therapeutic
molecular tools to eliminate toxic RNAs, to release the
sequestrated mediators or to removed expanded repeats in
the DMPK gene should also be efficient in brain cells. This is
strengthened by experiments performed in DM1 iPS and DM1
iPS-derived NSC (Xia et al., 2015; Gao et al., 2016). Targeted
insertion of polyA signals using TALEN in the DMPK gene
upstream the CTG repeat expansion eliminated transcripts
with expansions, RNA foci and reverse abnormal splicing in
the DM1 NSC. The next important challenges for all DM
therapeutics approaches will be to face the multi-systemic issue
of the disease and to improve efficiency, pharmacokinetics, bio-
distribution/delivery/availability, and safety with regards
to immune response and gene therapy specificity. Bio-
distribution/delivery/availability will be important steps
and need to take into account recent finding indicating that
cell membranes in DM1 tissues including muscles and possibly
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heart and brain are not compromised and may keep their
barrier capacity (Gonzalez-Barriga et al., 2015). Furthermore,
the blood brain barrier (BBB) is an additional barrier to cross
before to reach the CNS. Soluble drugs depending on the
molecule size and charge might be easier for systemic application
and for reaching CNS but they must have high efficacy and
low toxicity. Modifications of ASOs are intensively studied
especially by pharmaceutical companies to improve cell uptake
and bioavailability in tissues, biosystemic distribution, and
distribution in the brain via intrathecal injection into the CSF
(Geary et al., 2015). For gene therapy, including CRISPR-Cas
and TALE nucleases, viral approaches especially adenovirus
associated virus (AAV) vectors can be considered although
progress has to be made for better targeting and to reduce
immune response (Swiech et al., 2015; de Solis et al., 2016;
Lee et al., 2016; Ma et al., 2016; Murlidharan et al., 2016).
Nanotechnologies as well as cell-penetrated peptides are very
promising tools and might help to enable transport across the
BBB via intracranial, systemic, or intranasal administration
(Krupa et al., 2014; McGowan et al., 2015, 2016; Bai et al., 2016;
Kristensen et al., 2016; Sharma et al., 2016; Zhang et al., 2016).
Finally, the possibility to modify stem cells open a possible route
toward autologous cell transfer (Xia et al., 2015; Gao et al., 2016).
Another very important issue will be to target different brain
cell types including neurons, astrocytes, and probably others
glia cells. More studies are needed to determine the role of each
brain cell type in the pathophysiological defects observed in DM
CNS. Of course all strategies developed for DM1 will beneficiate
to DM2 with transposition to DM2 specificities (CCTG repeat
mutation, expression of CNBP in which lies the DM2 expansion).
CONCLUSION
Althoughmany fundamental aspects of themechanisms involved
in DM remained to be unraveled especially in brain, significant
progress has been made in recent years. This covers several
aspects that have benefited also from new developments
performed in DM muscles and heart. Table 2 summarizes the
state of the art for the development of new molecular therapeutic
strategies that can be applied to CNS. Starting from the proofs
of concept, the development of therapeutic tools to target DNA,
RNA, or proteins and high-throughput systems in cells or
small organisms to screen for new drugs have already provided
relevant candidates (i.e., drugs, ASO, nucleases...). Next barriers
to overcome are to improve treatment efficiency, biodistribution,
and availability in brain as well as safety. Preclinical mouse
models are available and are complementary depending on the
therapeutic targets.Mbnl Ko mice will be suitable for therapeutic
approaches aiming at restoring MBNL functions and transgenic
DMSXL can be used for strategies targeting, DNA, RNA, or
proteins. Other mouse models may also be helpful, but require
further characterization for CNS (this includes conditional
mouse models for RNA toxicity, for CELF1 overexpression and
Dmpk knockin mice, reviewed in Gomes-Pereira et al., 2011).
If molecular outputs can be easily defined for both Mbnl Ko
and DMSXL mice, possible biomarkers traceable in blood or
CSF remain to be identified and could give information about
possible blood and CSF biomarkers for human DM patients.
Behavioral abnormalities have been identified in both models,
but practical and easily applicable protocols for preclinical testing
should be specified bearing in mind relevance to human DM
diseases. For future clinical trials, many recent studies in DM
TABLE 2 | State of the art for new DM therapeutic development in CNS.
Proofs of concept Drugs ASO Gene therapy
DNA ∼ ∼
RNA
Mediators
Cells (ES, iPS, NSC)
Small organisms ?
Biodistribution in Mammals CNS +/− ? ?
Preclinical feasibility Mbnl Ko DMSXL Other existing models
DNA ?
RNA ?
Mediators ?
Molecular Output
RNA foci ?
Splicing defects mild ?
Final target proteins ?
Histopathology ? ? ?
Tau pathology ? ? ?
Biomarkers
Blood ? ? ?
CSF ? ? ?
Phenotypes
Imaging ? ? ?
Behavior ?
Sleep ? ?
Fatigue ? ? ?
Clinical assay DM1 CDM DM2
Inclusion Criteria
Age
Severity
C(C)TG repeat length
Clinical Output
Imaging
Neuropsy
Cognition
Sleep
Fatigue
CSF Biomarkers
Ab42 ? ?
Tau ? ?
other (IgG, MBP...) ?
Blood Biomarkers
BDNF ? ?
Not applicable; done or applicable; ? to be determined; applicable, must be
defined for trials, ∼ more or less. Existing symptomatic treatments are not included.
ES, Embryonic stem cells; iPS, induced pluripotent cells; NSC, neural stem cells; ASO,
antisense oligonucleotides; CSF, cerebrospinal fluid.
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patients have provided finding that will help to determine
inclusion criteria, clinical outputs as well as CSF and blood
biomarkers. Even though longitudinal studies and attempts to
correlate imaging changes with neurological symptoms have
emerged significantly, further research on homogeneous cohort
of DM1 (congenital, childhood, juvenile, adult, late-onset) and
DM2 patients is needed to establish protocols for future trials.
All these different issues were discussed during workshops of the
international DM-CNS group, reflecting an international effort
to combat DM neurological deficits (Axford and Pearson, 2013;
Bugiardini et al., 2014; Bosco et al., 2015).
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